In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology (KURA – Research Report), with a price target of $24.00.
Charles Zhu has given his Buy rating due to a combination of factors including Kura Oncology’s strategic advancements and financial health. The company has provided a promising update on its FY 2024 earnings, highlighting the anticipated timeline for the KOMET-017 data and the presentation of full monotherapy topline data at ASCO. This data is crucial as it could lead to accelerated approval in the US for frontline NPM1m and KMT2Ar AML.
Additionally, Kura’s strong cash position, with $727.4 million in cash and equivalents as of December 31, 2024, ensures an operational runway into 2027. This financial stability, coupled with strategic partnerships like the one with Kyowa Kirin, positions Kura favorably against competitors. The company’s preparation for commercialization and targeted sales efforts further bolster confidence in its growth potential.
Zhu covers the Healthcare sector, focusing on stocks such as Merus, IDEAYA Biosciences, and Kura Oncology. According to TipRanks, Zhu has an average return of -11.7% and a 30.49% success rate on recommended stocks.